病例报告:与抗Yo抗体相关的瘤性小脑退化与ofatumumabb成功治疗
Jingjing Dou1, Xiaotong Yue1, Haitao Ren2
1Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Frontiers in immunology
|December 31, 2024
概括
这项研究详细介绍了一种具有挑战性的神经瘤小脑退化 (PCD) 病例,该病例具有抗Yo抗体. 用ofatumumab治疗显示部分缓解症状,为这种罕见的神经综合征提供了潜在的新治疗途径.
科学领域:
- 神经免疫学 神经免疫学
- 在瘤学瘤学.
- 神经学 神经学
背景情况:
- 脑小脑神经变 (PCD) 是一种罕见的由癌症引发的自身免疫性疾病,具有诊断和治疗方面的挑战.
- 抗Yo抗体是PCD的常见标志物,但诊断可能是复杂的.
- 目前PCD的管理策略通常涉及免疫疗法,成功率可变.
关键词:
CD20 CD20 是一个CD20 CD20 是一个CD20.CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR3 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 CDR2 is what is what is what is what is what is在CDR2L中,CDR2L是指CDR2L.抗Yo抗体的抗Yo抗体.的一个atumumab.脑小变性瘤性脑小变性相关概念视频
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
222
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
222
Autoimmune Disorders
385
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
385
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147


